867 related articles for article (PubMed ID: 14734632)
1. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
3. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease.
Gao HM; Liu B; Zhang W; Hong JS
FASEB J; 2003 Oct; 17(13):1954-6. PubMed ID: 12897068
[TBL] [Abstract][Full Text] [Related]
4. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.
Liu Y; Qin L; Li G; Zhang W; An L; Liu B; Hong JS
J Pharmacol Exp Ther; 2003 Apr; 305(1):212-8. PubMed ID: 12649371
[TBL] [Abstract][Full Text] [Related]
5. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage.
Li G; Cui G; Tzeng NS; Wei SJ; Wang T; Block ML; Hong JS
FASEB J; 2005 Apr; 19(6):489-96. PubMed ID: 15790998
[TBL] [Abstract][Full Text] [Related]
6. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice.
Sun L; Xu S; Zhou M; Wang C; Wu Y; Chan P
Brain Res; 2010 Jun; 1335():74-82. PubMed ID: 20380823
[TBL] [Abstract][Full Text] [Related]
7. 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro.
Zhang W; Shin EJ; Wang T; Lee PH; Pang H; Wie MB; Kim WK; Kim SJ; Huang WH; Wang Y; Zhang W; Hong JS; Kim HC
FASEB J; 2006 Dec; 20(14):2496-511. PubMed ID: 17142799
[TBL] [Abstract][Full Text] [Related]
8. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.
Anandhan A; Tamilselvam K; Radhiga T; Rao S; Essa MM; Manivasagam T
Brain Res; 2012 Jan; 1433():104-13. PubMed ID: 22138428
[TBL] [Abstract][Full Text] [Related]
9. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity.
Zhang W; Qin L; Wang T; Wei SJ; Gao HM; Liu J; Wilson B; Liu B; Zhang W; Kim HC; Hong JS
FASEB J; 2005 Mar; 19(3):395-7. PubMed ID: 15596482
[TBL] [Abstract][Full Text] [Related]
10. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease.
Chung YC; Kim SR; Jin BK
J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
15. Amiloride is neuroprotective in an MPTP model of Parkinson's disease.
Arias RL; Sung ML; Vasylyev D; Zhang MY; Albinson K; Kubek K; Kagan N; Beyer C; Lin Q; Dwyer JM; Zaleska MM; Bowlby MR; Dunlop J; Monaghan M
Neurobiol Dis; 2008 Sep; 31(3):334-41. PubMed ID: 18606547
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease.
Watanabe Y; Himeda T; Araki T
Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202
[TBL] [Abstract][Full Text] [Related]
18. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
19. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease.
Gao HM; Liu B; Zhang W; Hong JS
FASEB J; 2003 Oct; 17(13):1957-9. PubMed ID: 12923073
[TBL] [Abstract][Full Text] [Related]
20. Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.
Liang Y; Li S; Zou Q; Su B
Neurosci Lett; 2006 Jun; 400(3):213-7. PubMed ID: 16540245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
